Events

July 17, 2025

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

The filing of our Registration Statement marks a significant step forward in our path to accessing the public capital markets and vision of bringing the next generation of safe and highly effective cancer therapies to patients.

May 20, 2025

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

Industry veteran to support acceleration of key pipeline projects and novel BiTAC antibody formats towards clinical studies.

May 5, 2025

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

The partnership combines VERAXA's proprietary ADC technology with OmniAb's antibody discovery technology for novel therapies targeting solid tumors.